Table 1.
Clinical characteristics of 1548 vaccinated patients with HM who developed COVID-19
| n | % | |
|---|---|---|
| Sex | ||
| Female/male | 661/887 | 42.7/57.3 |
| Age | ||
| Median, y (IQR) [range] | 66 (55-75) [18-96] | |
| <50/>50 y | 301/1247 | 19.5/80.5 |
| Comorbidities | ||
| None/1-2-3 comorbidities | 608/940 | 39.3/60.7 |
| Smoking history | 180 | 11.6 |
| Malignancy | ||
| Lymphoid malignancies | 1181 | 76.3 |
| Acute lymphoid leukemia | 64 | 4.1 |
| Chronic lymphoid leukemia | 211 | 13.6 |
| Hodgkin lymphoma | 65 | 4.2 |
| Non-Hodgkin lymphoma | 549 | 35.5 |
| Low grade | 289 | 18.7 |
| High grade | 260 | 16.8 |
| Multiple myeloma | 275 | 17.8 |
| Amyloid light-chain amyloidosis | 10 | 0.6 |
| Hairy cell leukemia | 7 | 0.5 |
| Myeloid malignancies | 356 | 23.0 |
| Acute myeloid leukemia | 140 | 9.0 |
| Chronic myeloid leukemia | 44 | 2.8 |
| Essential thrombocythemia | 18 | 1.2 |
| Myelodysplastic syndromes | 93 | 6.0 |
| Low-intermediate risk | 69 | 4.5 |
| High risk | 23 | 1.5 |
| Myelofibrosis | 39 | 2.5 |
| Polycythemia vera | 16 | 1.0 |
| Systemic mastocytosis | 6 | 0.4 |
| Aplastic anemia | 11 | 0.7 |
| Malignancy status before COVID-19 | ||
| Controlled disease | 821 | 53.0 |
| Complete remission | 524 | 33.9 |
| Partial remission | 297 | 19.2 |
| Stable disease | 322 | 20.8 |
| Active disease | 365 | 23.6 |
| Onset | 185 | 12.0 |
| Refractory/resistant | 180 | 11.6 |
| Unknown | 40 | 2.6 |
| Last malignancy treatment | ||
| Allo-HSCT | 76 | 4.9 |
| Auto-HSCT | 16 | 1 |
| CAR-T | 8 | 0.5 |
| Chemotherapy | ||
| Conventional chemotherapy | 234 | 15.1 |
| Demethylating agents | 80 | 5.2 |
| Immunotherapy | 146 | 5.7 |
| Immuno-chemotherapy | 562 | 36.3 |
| Targeted therapy | 311 | 20.1 |
| Supportive measures | 36 | 2.3 |
| No treatment | 136 | 8.8 |
| Vaccination | ||
| 1 dose | 129 | 8.3 |
| 2 doses (or J&J) | 770 | 49.7 |
| 3 doses | 639 | 41.3 |
| 4 doses | 10 | 0.6 |
| Type of vaccine | ||
| mRNA | 1377 | 89.0 |
| BioNTech/Pfizer | 1121 | 72.4 |
| Moderna COVE | 256 | 16.5 |
| Vector-based | 133 | 8.6 |
| AstraZeneca Oxford | 99 | 6.4 |
| Sputnik | 13 | 0.8 |
| J&J (Janssen) | 21 | 1.4 |
| Inactivated | 38 | 2.5 |
| CoronaVac/Sinovac | 21 | 1.4 |
| Sinopharm | 17 | 1.1 |
| Spike protein dosage after vaccination∗ | ||
| No response | 135 | 8.7 |
| Weak response | 34 | 2.2 |
| Optimal response | 75 | 4.8 |
| Not tested | 1304 | 84.2 |
| COVID-19 infection | ||
| Wild type | 40 | 2.6 |
| Alpha | 34 | 2.2 |
| Beta | 1 | 0.1 |
| Delta | 161 | 10.4 |
| Omicron | 517 | 33.4 |
| Not tested | 795 | 51.4 |
| Severity | ||
| Asymptomatic | 283 | 18.3 |
| Mild infection | 604 | 39.0 |
| Severe infection | 509 | 32.9 |
| Critical infection | 152 | 9.8 |
| Symptomatology at onset | ||
| Asymptomatic | 306 | 19.8 |
| Pulmonary | 528 | 34.1 |
| Pulmonary + extrapulmonary | 400 | 25.8 |
| Extrapulmonary | 314 | 20.3 |
| Stay during COVID-19 | ||
| Hospital | 823 | 53.2 |
| ICU | 152 | 9.8 |
| Home | 800 | 51.7 |
CAR-T, chimeric antigen receptor T cells; HSCT, hematopoietic stem cell transplantation.
∗
Referring to the World Health Organization international standards, binding antibody units per milliliter (https://www.who.int/news-room/feature-stories/detail/standardization-of-vaccines-for-coronavirusdisease-covid-19).